In a report released today, Alethia Young from Cantor Fitzgerald maintained a Buy rating on Ascendis Pharma (ASND), with a price target of $185. The company’s shares opened today at $128.34, close to its 52-week high of $131.76.
According to TipRanks.com, Young is a 5-star analyst with an average return of 9.3% and a 52.9% success rate. Young covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Vertex Pharmaceuticals, and Sarepta Therapeutics.
Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $153.80, implying a 19.8% upside from current levels. In a report issued on March 4, Canaccord Genuity also maintained a Buy rating on the stock with a $132 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $131.76 and a one-year low of $53.21. Currently, Ascendis Pharma has an average volume of 376.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market.
